Transient Ischemic Attack News and Research

RSS

A transient ischemic attack (TIA) is a transient stroke that lasts only a few minutes. It occurs when the blood supply to part of the brain is briefly interrupted. TIA symptoms, which usually occur suddenly, are similar to those of stroke but do not last as long. Most symptoms of a TIA disappear within an hour, although they may persist for up to 24 hours. Symptoms can include: numbness or weakness in the face, arm, or leg, especially on one side of the body; confusion or difficulty in talking or understanding speech; trouble seeing in one or both eyes; and difficulty with walking, dizziness, or loss of balance and coordination.

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals.

17 Aug 2013

Study evaluates implementation of out-of hospital stroke policy in some Chicago hospitals

Implementing an out-of hospital stroke policy in some Chicago hospitals was associated with significant improvements in emergency medical services use and increased intravenous tissue plasminogen activator use at primary stroke centers, according to a study published by JAMA Neurology.

2 Jul 2013

Research: Stroke patients may be more likely to develop problems with memory and thinking

People who experience any stroke symptoms—but do not have a stroke—may also be more likely to develop problems with memory and thinking, according to new research published in the June 19, 2013, online issue of Neurology®, the medical journal of the American Academy of Neurology.

20 Jun 2013

Study: One in four stroke survivors suffer from symptoms of PTSD

One in four people who survive a stroke or transient ischemic attack suffer from symptoms of post-traumatic stress disorder within the first year post-event, and one in nine experience chronic PTSD more than a year later.

20 Jun 2013

Smartphone solutions for clinical trials

mHealth broadly refers to the use of a mobile device to send patient information to or from a medical service provider. In most medication management mobile applications that are out there now, the “information” sent is usually a unidirectional nagging reminder to the patient. The application may populate a diary or it may not.

24 May 2013

Implantation of new mechanical heart valve reduces anticoagulation therapy in AVR patients

For more than 40 years, patients under 65 years of age requiring heart valve replacement have had to choose between a mechanical valve that offers life-long durability but requires aggressive warfarin anticoagulation or a biological (cow or pig) valve that will wear out in 10-20 years but does not require anticoagulation.

7 May 2013

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LIPTRUZET (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.

4 May 2013

Undetected arrhythmia could underlie some wake-up strokes

Unrecognized atrial fibrillation could be a cause of some wake-up strokes, say researchers who found an increased prevalence of the arrhythmia in patients who had stroke symptoms on waking.

29 Apr 2013

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the U.S. Food and Drug Administration (FDA) has approved ABILIFY MAINTENA (aripiprazole) for extended- release injectable suspension, an intramuscular (IM) depot formulation indicated for the treatment of schizophrenia.

1 Mar 2013

Dabigatran decreases risk of recurrent venous thromboembolism

New findings from two double-blind, randomized trials, RE-MEDY and RE-SONATE, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE).

21 Feb 2013

Study assesses ischaemic and haemorrhagic risk linked with history of stroke or TIA

Heart and cerebro-vascular disorders represent the two leading causes of death throughout the world. They are sometimes combined in a single patient and their combination represents both a considerable risk to the patient and a therapeutic challenge.

20 Feb 2013

Positive data from POZEN's PA32540 Phase 3 studies presented at AHA 2013 stroke conference

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented data today from the combined results of two Phase 3 studies of PA32540, an antiplatelet therapy of enteric-coated (EC) and immediate-release omeprazole, in patients with previous cerebrovascular disease.

10 Feb 2013

Marijuana may double stroke risk in young adults

Marijuana, the most widely used illicit drug, may double stroke risk in young adults, according to research presented at the American Stroke Association's International Stroke Conference 2013.

9 Feb 2013

New evidence supports thrombolysis in presence of contraindications

A Norwegian study offers further evidence to support the use of intravenous thrombolysis to treat stroke even in patients with contraindications to the drug.

25 Jan 2013

Low-income groups slow to seek treatment for stroke

People with lower incomes are less likely to present at a hospital within 3 hours of stroke symptoms and thus have lower rates of thrombolysis therapy or post-stroke care than their more affluent counterparts, according to a retrospective analysis.

22 Jan 2013

Stroke patients with PTSD less likely to adhere to treatment regimens

A new survey of stroke survivors has shown that those with post-traumatic stress disorder (PTSD) are less likely to adhere to treatment regimens that reduce the risk of an additional stroke. Researchers found that 65 percent of stroke survivors with PTSD failed to adhere to treatment, compared with 33 percent of those without PTSD.

18 Jan 2013

Updated U.S. prescribing information for Boehringer Ingelheim’s Pradaxa

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. prescribing information for Pradaxa (dabigatran etexilate mesylate) capsules was updated to include a contraindication related to use in patients with mechanical prosthetic heart valve replacement.

21 Dec 2012

AHA/ASA identify top cardiovascular and stroke research advances for 2012

Resuscitation, cell regeneration, a new high blood pressure treatment and developments in devices for treating stroke are among the key scientific findings that make up this year's top cardiovascular and stroke research identified by the American Heart Association and American Stroke Association.

18 Dec 2012

Survey identifies career burnout as significant problem among hospital-based neurologists

A survey has identified career burnout as a significant problem among neurologists who predominantly work with hospital inpatients.

14 Dec 2012

Ischemic stroke: an interview with Dr Gregory Ford

A stroke is a sudden interruption of blood flow to the brain which deprives the brain of oxygen and nutrients. Approximately two millions brain cells die each minute during a stroke. This can lead to brain damage, physical and mental disability and death.

1 Nov 2012